Si-Bone (NSDQ:SIBN) said today that it expects to record fourth-quarter sales of $15.4 million to $15.6 million, up 12 – 13% from the same period last year. The company pegged its full-year sales for 2018 between $55.2 million and $55.4 million, up 15% from 2017. Analysts on Wall Street are expecting Si-Bone to post Q4 sales […]
Si-Bone
Si-Bone closes $124m IPO
Si-Bone (NSDQ:SIBN) last week closed an initial public offering that brought in much more than anticipated for its iFuse sacroiliac implant. The Santa Clara, Calif.-based company priced the 7.2-million-share flotation at $15 per share, which at $108 million would have topped its initial range of about $90 million to nearly $104 million (which itself would have beaten […]
Si-Bone prices upsized $108m IPO
Si-Bone yesterday priced its initial public offering, which launched today, lifting the total it hopes to bring in from a previous maximum of $103.5 million up to $108 million. In the offering, the Santa Clara, Calif.-based company said it will offer 7.2 million shares at $15 per share. Si-Bone had previously said it expected to offer […]
Si-Bone sets price range for $104m IPO
Si-Bone has set a price range for its upcoming initial public offering, looking to bring in between $89.7 million and $103.5 million, according to an SEC filing posted late last week The Santa Clara, Calif.-based company said that it plans to offer 6.9 million shares at between $13 and $15 per share in the offering, and […]
Si-Bone registers for $98m IPO
Si-Bone yesterday registered for an initial public offering, looking to bring in approximately $97.8 million, according to an SEC filing. The Santa Clara, Calif.-based company said that it plans to list on the Nasdaq Global Market under the ticker symbol “SIBN.” Morgan Stanley and BofA Merrill Lynch are acting as joint book-running managers for the IPO, […]
Si-Bone touts French iFuse reimbursement win
Si-Bone today touted that France is adding the iFuse implant system to its List of Refundable Products and services, clearing it for reimbursement by the French National Healthcare System. The decision comes following the favorable opinion of the National Commissions for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS), the Santa Clara, Calif-based company said. […]
Si-Bone touts iFuse implant coverage across 23 insurers
Si-Bone today touted that its iFuse implant system has received positive coverage policies from 23 commercial health plans. The triangular implant designed to treat the sacroiliac joint has now received published exclusive positive coverage policies from Blue Cross Blue Shield plans in Florida, Illinois, New Mexico, Oklahoma, Texas, Montana, Idaho, South Carolina, Kansas, Louisiana, Massachusetts, Minnesota, […]
Si-Bone touts BCBS SI joint fusion operation assessment rating upgrade
Si-Bone today touted that the Blue Cross Blue Shield Association assigned triangular implants for SI joint fusion, including the company’s iFuse implant, as a “moderate” quality evidence recommendation after an extensive review of safety and effectiveness data on the devices and procedures. The “moderate” grade is the second highest on BCBSA’s four-tier rating system, according to […]
7 medtech stories we missed this week: Aug. 18, 2017
From Nemaura’s new Oceania distribution deal to Sanuwave’s promissory note expansion, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Nemaura inks Oceania distribution deal for SugarBeat patch Nemaura announced in an Aug. 15 press release that it has signed a non-binding distribution deal with Device Technologies for […]
